Investigate Gilead Patent Deals, AIDS Activists Urge NY

Law360, New York (August 31, 2017, 4:18 PM EDT) -- Gilead Sciences Inc. entered into pay-for-delay settlements that were likely illegal with companies trying to bring a generic version of its blockbuster HIV treatment and prevention medication Truvada on the market, a group of HIV/AIDS activists have told New York’s attorney general in urging him to launch an investigation.

Seven companies have sought U.S. Food and Drug Administration approval for a generic version of Truvada and challenged the patents that protect it. Gilead, however, subsequently sued those companies for patent infringement and reached confidential settlements that presumably kept the generics off the market for a set period of time, the Aug....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS